BAM
CPRX

Belpointe Asset Management’s Catalyst Pharmaceutical CPRX Stock Holding History

Belpointe Asset Management’s Portfolio CPRX Stock Details CPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,312
Closed -$54.9K – 1128
2023
Q1 		$54.9K Sell
3,312
-9,713
-75% -$160K ﹤0.01% 1649
2022
Q4 		$242K Buy
+13,025
New +$201K 0.01% 807

Other funds holding CPRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Belpointe Asset Management's CPRX Position: Q2 2023 in Review

Belpointe Asset Management sold out of Catalyst Pharmaceutical (CPRX) in Q2 2023, closing a stake of 3,312 shares — an estimated $54.9K sold.

Belpointe Asset Management first reported a position in CPRX in Q4 2022 and held it in 2 quarters. The position peaked at $242K in Q4 2022. 248 funds tracked by Wall St. Rank hold CPRX as of Q2 2023.

  • Belpointe Asset Management reported no remaining Catalyst Pharmaceutical position as of Q2 2023 after selling out during the quarter.
  • Belpointe Asset Management sold 3,312 Catalyst Pharmaceutical shares in Q2 2023, an estimated $54.9K.
  • Belpointe Asset Management first reported a position in Catalyst Pharmaceutical in Q4 2022 and held it in 2 quarters.
  • Belpointe Asset Management's Catalyst Pharmaceutical position peaked at $242K in Q4 2022.
  • 248 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q2 2023.

Based on Belpointe Asset Management's 13F filing for Q2 2023, filed 15 Aug 2023.